News

Researchers Develop New Animal Model of Multiple Myeloma

Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma, which will hopefully allow researchers to better understand the pathology and physiology involved in the development of the disease and test new potential therapeutic agents. The…

Potential Therapeutic Target for Drug-resistant Multiple Myelomas Identified in Study

A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according to  researchers at the Tokyo Women’s Medical University. The study, “Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma,” published in …

Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma

Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination of once-weekly oral Ninlaro (ixazomib) capsules and lenalidomide-dexamethasone or placebo and lenalidomide-dexamethasone. The results, also presented at the 57th Annual Meeting of the American Society of Hematology (ASH)…

International Myeloma Foundation Funds First Broad Screening of Disease at Earliest Stage

The International Myeloma Foundation (IMF) has announced new funding for the first comprehensive screening study that aims to prevent myeloma before it develops. The funded study, titled “iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma),” will examine blood samples from 140,000 people in Iceland over the age of 40, seeking the earliest signs of the…

Multiple Myeloma Cancer Stem Cells Decreased with Novel Antibody Medi-551

A preliminary clinical study at Johns Hopkins Kimmel Cancer Center demonstrated that antibody treatment could decrease by half the number of cancer stem cells, which control the progression of cancer in almost all patients suffering from multiple myeloma. The efficiency of the antibody MEDI-551 was studied in 15 patients suffering from…

Study Explores Challenges of Treating Myeloma in the Elderly

The diagnosis and management of myeloma in the very elderly is especially challenging, despite improvements in therapies. A review study, “Multiple myeloma in the very elderly patient: challenges and solutions, published in Clinical Interventions in Aging, suggested ways of overcoming the difficulties to maximize these patients’ length and quality of life. New drug development has…

MedImmune’s Antibody Therapy Seen to Effectively Reduce Cancer Stem Cells in Most Newly Diagnosed Multiple Myeloma Patients

A research team led by William Matsui, MD, and Carol Ann Huff, MD, with the Johns Hopkins Kimmel Cancer Center, has found that MedImmune’s novel MEDI-551 antibody treatment effectively decreased the number of cancer stem cells, which drive the growth of cancer, in most patients with recently diagnosed multiple myeloma. Study results will be…